B-intervention	0	10	Cimicifuga
I-intervention	11	19	racemosa
O	20	23	for
O	24	27	the
O	28	37	treatment
O	38	40	of
B-condition	41	44	hot
I-condition	45	52	flushes
O	53	55	in
B-eligibility	56	61	women
I-eligibility	62	71	surviving
I-eligibility	72	78	breast
I-eligibility	79	85	cancer
O	85	86	.

O	87	89	To
O	90	97	examine
O	98	101	the
O	102	108	effect
O	109	111	of
O	112	122	Cimicifuga
O	123	131	racemosa
O	132	133	(
O	133	135	CR
O	136	139	BNO
O	140	144	1055
O	144	145	)
O	146	148	on
O	149	152	hot
O	153	160	flushes
O	161	167	caused
O	168	170	by
O	171	180	tamoxifen
O	181	189	adjuvant
O	190	197	therapy
O	198	200	in
O	201	206	young
O	207	220	premenopausal
O	221	227	breast
O	228	234	cancer
O	235	244	survivors
O	244	245	.

O	246	250	This
O	251	260	treatment
O	261	269	presents
O	270	272	an
O	273	276	off
O	276	277	-
O	277	282	label
O	283	286	use
O	287	289	of
O	290	292	CR
O	293	296	BNO
O	297	301	1055
O	301	302	.

O	303	310	Between
O	311	314	May
O	315	319	1999
O	320	323	and
O	324	332	December
O	333	337	2001
O	337	338	,
O	339	341	we
O	342	349	accrued
B-total-participants	350	353	136
O	354	360	breast
O	361	367	cancer
O	368	377	survivors
O	378	382	aged
O	383	385	35
O	385	386	-
O	386	388	52
O	389	394	years
O	394	395	.

O	396	401	After
O	402	411	treatment
O	412	416	with
O	417	426	segmental
O	427	429	or
O	430	435	total
O	436	446	mastectomy
O	446	447	,
O	448	457	radiation
O	458	465	therapy
O	466	469	and
O	470	478	adjuvant
O	479	491	chemotherapy
O	491	492	,
O	493	505	participants
O	506	510	were
O	511	513	in
O	514	518	open
O	518	519	-
O	519	524	label
O	525	533	randomly
O	534	542	assigned
O	543	544	(
O	544	545	1
O	545	546	-
O	546	547	2
O	547	548	)
O	549	551	to
O	552	559	receive
O	560	569	tamoxifen
O	570	572	20
O	573	575	mg
O	576	579	per
O	580	583	day
O	584	590	orally
O	591	592	(
B-control	592	597	usual
I-control	597	598	-
I-control	598	602	care
I-control	603	608	group
O	608	609	;
O	610	611	n
O	611	612	=
B-control-participants	612	614	46
O	614	615	)
O	616	618	or
O	619	628	tamoxifen
O	629	630	(
O	630	634	same
O	635	639	dose
O	640	643	and
O	644	652	posology
O	652	653	)
O	654	658	plus
O	659	661	CR
O	662	665	BNO
O	666	670	1055
O	671	672	(
O	672	679	Menofem
O	679	680	/
O	680	690	Klimadynon
O	690	691	,
O	692	705	corresponding
O	706	708	to
O	709	711	20
O	712	714	mg
O	715	717	of
O	718	724	herbal
O	725	729	drug
O	729	730	;
O	731	743	intervention
O	744	749	group
O	750	751	n
O	751	752	=
B-intervention-participants	752	754	90
O	754	755	)
O	755	756	.

O	757	765	Duration
O	766	768	of
O	769	778	treatment
O	779	782	was
O	783	784	5
O	785	790	years
O	791	794	for
O	795	804	tamoxifen
O	804	805	,
O	806	815	according
O	816	818	to
O	819	832	international
O	833	842	standards
O	843	846	for
O	847	855	adjuvant
O	856	865	therapies
O	865	866	,
O	867	870	and
O	871	873	12
O	874	880	months
O	881	884	for
O	885	887	CR
O	888	891	BNO
O	892	896	1055
O	896	897	.

O	898	904	Follow
O	904	905	-
O	905	907	up
O	908	916	included
O	917	925	clinical
O	926	936	assessment
O	937	942	every
O	943	944	2
O	945	951	months
O	951	952	;
O	953	956	the
O	957	964	primary
O	965	973	endpoint
O	974	977	was
O	978	980	to
O	981	987	record
O	988	991	the
B-outcome-Measure	992	998	number
I-outcome-Measure	999	1002	and
I-outcome-Measure	1003	1012	intensity
I-outcome-Measure	1013	1015	of
I-outcome-Measure	1016	1019	hot
I-outcome-Measure	1020	1027	flushes
O	1027	1028	.

O	1029	1038	Comparing
O	1039	1047	patients
O	1048	1056	assigned
O	1057	1059	to
O	1060	1065	usual
O	1065	1066	-
O	1066	1070	care
O	1071	1076	group
O	1077	1081	with
O	1082	1087	those
O	1088	1096	assigned
O	1097	1099	to
O	1100	1112	intervention
O	1113	1118	group
O	1118	1119	,
O	1120	1123	the
O	1124	1130	number
O	1131	1134	and
O	1135	1143	severity
O	1144	1146	of
O	1147	1150	hot
O	1151	1158	flushes
O	1159	1163	were
O	1164	1171	reduced
O	1172	1177	after
O	1178	1190	intervention
O	1190	1191	.

O	1192	1198	Almost
O	1199	1203	half
O	1204	1206	of
O	1207	1210	the
O	1211	1219	patients
O	1220	1222	of
O	1223	1226	the
O	1227	1239	intervention
O	1240	1245	group
O	1246	1250	were
O	1251	1255	free
O	1256	1258	of
O	1259	1262	hot
O	1263	1270	flushes
O	1270	1271	,
O	1272	1277	while
B-outcome	1278	1284	severe
I-outcome	1285	1288	hot
I-outcome	1289	1296	flushes
O	1297	1301	were
O	1302	1310	reported
O	1311	1313	by
B-iv-bin-percent	1314	1316	24
I-iv-bin-percent	1316	1317	.
I-iv-bin-percent	1317	1318	4
I-iv-bin-percent	1318	1319	%
O	1320	1322	of
O	1323	1331	patients
O	1332	1334	of
O	1335	1347	intervention
O	1348	1353	group
O	1354	1357	and
B-cv-bin-percent	1358	1360	73
I-cv-bin-percent	1360	1361	.
I-cv-bin-percent	1361	1362	9
I-cv-bin-percent	1362	1363	%
O	1364	1366	of
O	1367	1370	the
O	1371	1376	usual
O	1376	1377	-
O	1377	1381	care
O	1382	1387	group
O	1388	1389	(
O	1389	1390	P
O	1390	1391	<
O	1391	1392	0
O	1392	1393	.
O	1393	1395	01
O	1395	1396	)
O	1396	1397	.

B-outcome	1398	1401	Hot
I-outcome	1402	1409	flushes
O	1410	1414	were
O	1415	1418	the
O	1419	1423	most
O	1424	1432	frequent
O	1433	1440	adverse
O	1441	1449	reaction
O	1450	1452	to
O	1453	1462	tamoxifen
O	1463	1471	adjuvant
O	1472	1479	therapy
O	1480	1482	in
O	1483	1489	breast
O	1490	1496	cancer
O	1497	1506	survivors
O	1506	1507	.

O	1508	1511	The
O	1512	1520	combined
O	1521	1535	administration
O	1536	1538	of
O	1539	1548	tamoxifen
O	1549	1553	plus
O	1554	1556	CR
O	1557	1560	BNO
O	1561	1565	1055
O	1566	1569	for
O	1570	1571	a
O	1572	1578	period
O	1579	1581	of
O	1582	1584	12
O	1585	1591	months
O	1592	1599	allowed
O	1600	1612	satisfactory
O	1613	1622	reduction
O	1623	1625	in
O	1626	1629	the
O	1630	1636	number
O	1637	1640	and
O	1641	1649	severity
O	1650	1652	of
O	1653	1656	hot
O	1657	1664	flushes
O	1664	1665	.
